BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Mounjaro leads India's Top 10 Pharma brands with 229.4% MAT Growth in October 2026

14 November 2026 | News | By Narayan Kulkarni

Eli Lilly's Mounjaro tops the brand rankings with Rs 1,544 crore in sales, while nine of the top 10 brands record positive MAT growth



Mounjaro from Eli Lilly emerged as India's largest pharmaceutical brand in October 2026, recording moving annual total (MAT) sales of Rs 1,544 crore and an impressive 229.4 per cent growth, according to data from Pharmarack Technologies.

Among the top 10 pharmaceutical brands ranked by MAT sales, Mounjaro retained the number one position, significantly ahead of Augmentin from GSK, which ranked second with sales of Rs 984 crore and 13.9 per cent growth.

Glycomet GP from USV occupied the third position, recording sales of Rs 979 crore and 14.9 per cent growth. Foracort from Cipla ranked fourth with Rs 914 crore in sales, registering 12.9 per cent growth.

Pan from Alkem ranked fifth, with MAT sales of Rs 887 crore and 9.2 per cent growth. Zerodol SP from Ipca moved into sixth position, recording Rs 854 crore in sales and 29.9 per cent growth, the second-highest growth rate among the top 10 brands.

Clavam from Alkem secured the seventh position with sales of Rs 740 crore, growing 7 per cent. Liv.52 from Himalaya ranked eighth with Rs 733 crore in sales, but recorded a 3.9 per cent decline.

Mixtard from Abbott ranked ninth, with sales of Rs 724 crore, registering an 8.3 per cent contraction. Pan D from Alkem completed the top 10 with sales of Rs 719 crore and 4.3 per cent growth.

The rankings indicate that eight of the top 10 brands recorded positive MAT growth, while Liv.52 and Mixtard experienced declines. Mounjaro's exceptional growth reflects its rapidly expanding position in the Indian pharmaceutical market, while Zerodol SP also recorded strong double-digit expansion.

Overall, the Indian Pharmaceutical Market recorded MAT sales of Rs 2,66,510 crore in October 2026, registering 11.3 per cent growth.

Top 10 pharma brands – October 2026

Rank	Brand	Corporate	MAT sales (Rs Cr)	MAT growth
1	Mounjaro	Eli Lilly	1,544	229.4%
2	Augmentin	GSK	984	13.9%
3	Glycomet GP	USV	979	14.9%
4	Foracort	Cipla	914	12.9%

5	Pan	Alkem	887	9.2%
6	Zerodol SP	Ipca	854	29.9%
7	Clavam	Alkem	740	7.0%
8	Liv.52	Himalaya	733	-3.9%
9	Mixtard	Abbott	724	-8.3%
10	Pan D	Alkem	719	4.3%

Highlights

- Highest growth: Mounjaro (229.4%), followed by Zerodol SP (29.9%).
- Negative growth: Liv.52 (-3.9%) and Mixtard (-8.3%).
- Double-digit growth: Mounjaro, Augmentin, Glycomet GP, Foracort and Zerodol SP.
- Corporate presence: Alkem has three brands in the top 10, while Eli Lilly, GSK, USV, Cipla, Ipca and Himalaya account for the remaining seven.

Narayan Kulkarni

(narayan.kulkarni@mmactiv.com)